News

A topical treatment that breaks apart disulfide bonds between crystalline lens proteins was shown to increase accommodative amplitude and improve near visual acuity in a randomized, placebo-controlled clinical trial.

Early results from a repeatability and reproducibility study of a precision ultrasound device indicate the anterior segment imaging device can provide unique measurements on the cornea and will have multiple applications in the future.

Emerging trends and hot topics in eye and vision research filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.

An advanced, self-validating method is providing a new approach to IOL power selection, explains Warren E. Hill, MD, FACS.

Bausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.

The pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.

Allergan is moving forward with plans to introduce innovative drug delivery device and surgical device for glaucoma

The laws governing ophthalmic drug and device approvals have changed little in recent years. But the FDA is making significant and far-reaching changes in its approvals process.

Seven glaucoma drug delivery companies reviewed the latest data on platforms

Device manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.

Since glaucoma progresses faster in some patients than others, optical coherence tomography (OCT) and visual field progression analysis can be more useful than IOP in guiding treatment decisions.

A tsunami of glaucoma is sweeping toward the U.S. healthcare system, according to Cynthia Mattox, MD. For many ophthalmologists, coping with the increased demand will mean teaming up with other eye-care professionals.

Clinicians have a variety of tools and options at their disposal to treat narrow angle glaucoma. Sunita Radhakrishnan, MD, provided an overview of these possibilities.

Glaucoma progression occurs slowly in the vast majority of patients, and most patients with glaucoma will not go blind from the disease. However, it is important to get early diagnosis, treatment when indicated, and develop a disease surveillance protocol.

When glaucoma is progressing despite good intraocular pressure control, clinicians should consider a variety of issues before advancing patients along the therapeutic ladder.

Yvonne Ou, MD, reviewed the scientific evidence regarding the effects of various lifestyle practices on glaucoma and IOP.

Microinvasive glaucoma surgery devices already have transformed the management of glaucoma and will have a bigger impact in the future considering the options in the investigational pipeline and the opportunities they present.

Glaucoma is a common complication of uveitis, occurring in about 20% of affected eyes and arising through several different mechanisms.Here are seven common mistakes clinicians make in evaluating and managing elevated IOP in eyes with uveitis.

Ophthalmologists need to prepare their practices for the Value-Based Payment (VBP) program for Medicare services. VBP is a strategy to promote quality and value of health care services, with providers being paid based on value-of-care-delivered rather than volume. Regardless of the perspectives, the fact remains that reimbursement can increase or decrease substantially with the VBP program.

New agents and devices offer promise to control IOP and slow, perhaps even stop, the advancing vision loss that is common in glaucoma. Research and development to restore vision is starting to show significant results in preclinical models and early stage clinical trials.

Trimethoprim-sulfamethoxazole can be used both acutely and prophylactically in patients with Toxoplasma gondii retinochoroiditis.

Recently, I attended two public addresses. Neither of the speakers, I believe, are stupid. But neither (obviously) had a science background.

The intravitreal injection of a recombinant AAV2/2 vector with the wild-type ND4 gene might provide a safe and effective avenue to treat patients with Leber’s hereditary optic neuropathy.

Tailor antibiotic choices for each patient, as resistance remains high, according to the 2015 Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) update.

Dr. Harrie started a vision-screening program at a youth detention center which gives him and his team an opportunity to screen adolescents in the criminal justice system before they are assigned to a rehabilitation program or a long-term incarceration facility.

In the medical field, it is very common to see long distance relationships amongst healthcare professionals including medical students, residents, and fellows who are often in different training programs across the country.

So the next time you hand this task off to the human resources person to do, try jumping back in the saddle and taking the reins.

In the most recent update from the ARMOR study, Penny Asbell, MD, FACS, MBA, explained that clinicians must choose their antibiotics carefully.

Cataract surgery technology continues to advance with improvements that enhance surgical performance every step of the way.

Postoperative endophthalmitis remains a potentially devastating complication of cataract surgery. However, a good visual outcome is possible if the infection is recognized early and treated appropriately, said Harry W. Flynn Jr, MD.